(Lund, Sweden, April 23, 2020.) The company's largest owner, Inhalation Sciences Sweden AB (publ) ("ISAB"), today announced the sale of 1,790,000 shares in Ziccum AB (publ) ("Ziccum"), corresponding to ISAB's entire holding in Ziccum. The sale was made outside the market via Penser Bank on behalf of ISAB to stakeholders with a long-term interest in Ziccum. The buyers include three members of Ziccum AB's Board of Directors, Kristian Kierkegaard, Mikaela Bruhammar and Fredrik Sjövall.
Since the spin-off and listing of Ziccum, ISAB has been a passive shareholder in Ziccum, and the sale is in line with what both companies have previously communicated about ISAB's ambition to divest its holding.
Ziccum's CEO Göran Conradson: "We can see that the market showed great interest in ISAB's sale of sits hares in Ziccum. We're very pleased to add strong, long-term investors in Ziccum."
For more information about Ziccum, please contact:
Göran Conradson: CEO Ziccum AB
E-mail: conradson@ziccum.com
Mob: +46 709 61 55 99
About Ziccum
Ziccum AB (publ) develops new patented formulations of biological drugs where sensitivity to temperature differences, especially during transportation, currently limits medical and so commercial potential. The company's patented technology, LaminarPace, develops dry powder formulations of drugs and vaccines that currently only exist in liquid form. By doing so Ziccum can increase the availability of drugs and vaccines in existing markets-and open up new ones.